Analyst Upgrades Drive Legend Biotech Shares Higher Legend Biotech stock surged over 5% this week after the company reported $369 million in first-quarter sales for its CARVYKTI therapy, outpacing expectations. Multiple analysts, including Barclays and Jefferies, have maintained Buy ratings with price targets above $90, citing robust growth and a strong market position for the company.12